Therapy-related myelodysplastic syndrome following primary breast cancer

Leukemia Research

Volumn 47, Issue , 2016, Pages 178-184

  Malmgren, Judith A ^a,b   Calip, Gregory S ^c   Pyott, Shawna M ^d   Atwood, Mary K ^e   Kaplan, Henry G ^e  

^a HealthStat Consulting Inc   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d PHENOPATH LABORATORIES   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Prognosis; Survival; t MDS; Therapy related myelodysplasia; Therapy related myeloid neoplasm

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER REGISTRY; COMPLICATION; INCIDENCE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; REGISTER; SECOND CANCER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; REGISTRIES; SEER PROGRAM; STEM CELL TRANSPLANTATION;

EID: 84978114064     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2016.06.005     Document Type: Article

References (43)

1. [1] Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). fourth edition, 2008, World Health Organization Lyon, France.
2. [2] Thirman, M.J., Larson, R.A., Therapy-related myeloid leukemia. Hematol. Oncol. Clin. North Am. 10:2 (1996), 293–320.
3. [3] Kaplan, H.G., Malmgren, J.A., Atwood, M.K., Calip, G.S., Effect of treatment and mammography detection on breast cancer survival over time: 1990–2007. Cancer 121:15 (2015), 2553–2561.
4. [4] Wolff, A.C., Blackford, A.L., Visvanathan, K., Rugo, H.S., Moy, B., Goldstein, L.J., Stockerl-Goldstein, K., Neumayer, L., Langbaum, T.S., Theriault, R.L., Hughes, M.E., Weeks, J.C., Karp, J.E., Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J. Clin. Oncol. 33:4 (2015), 340–348.
5. [5] Matesich, S.M., Shapiro, C.L., Second cancers after breast cancer treatment. Semin. Oncol. 30:6 (2003), 740–748.
6. [6] Kaplan, H.G., Malmgren, J.A., Li, C.I., Calip, G.S., Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors. Breast Cancer Res. Treat. 142:3 (2013), 629–636.
7. [7] Kaplan, H.G., Malmgren, J.A., Atwood, M.K., Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990–2005. BMC Cancer, 11, 2011, 260.
8. [8] Kaplan, H., Malmgren, J., De Roos, A.J., Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study. Breast Cancer Res. Ttreat. 137:3 (2013), 863–867.
9. [9] De Roos, A.J., Deeg, H.J., Davis, S., A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 18:10 (2007), 1199–1208.
10. [10] Calip, G.S., Malmgren, J.A., Lee, W.J., Schwartz, S.M., Kaplan, H.G., Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. Breast Cancer Res. Treat. 154:1 (2015), 133–143.
11. [11] Smith, S.M., Le Beau, M.M., Huo, D., Karrison, T., Sobecks, R.M., Anastasi, J., Vardiman, J.W., Rowley, J.D., Larson, R.A., Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102:1 (2003), 43–52.
12. [12] Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U., Haase, D., Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:12 (2012), 2454–2465.
13. [13] Benesch, M., Deeg, H.J., Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin. Proc. 78 (2003), 981–990.
14. [14] Nimer, S.D., Myelodysplastic syndromes. Blood 111:10 (2008), 4841–4851.
15. [15] Cancer Surveillance System (contract No. N01-CN-67009), Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, Bethesda, MD. http://www.fhcrc.org/en/labs/phs/projects/cancer-surveillance-system.html.
16. [16] Fritz, A.G., International Classification of Diseases for Oncology: ICD-O. third edition, 2013, World Health Organization, Geneva (First revision. ed.).
17. [17] IBM Corp., Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.
18. [18] StataCorp, Stata Statistical Software: Release 14. 2015, StataCorp. LP, College Station, TX.
19. [19] Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A., Bloomfield, C.D., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:5 (2009), 937–951.
20. [20] Armitage, J.O., Carbone, P.P., Connors, J.M., Levine, A., Bennett, J.M., Kroll, S., Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J. Clin. Oncol. 1:5 (2003), 897–906.
21. [21] Granfeldt Ostgard, L.S., Medeiros, B.C., Sengelov, H., Norgaard, M., Andersen, M.K., Dufva, I.H., Friis, L.S., Kjeldsen, E., Marcher, C.W., Preiss, B., Severinsen, M., Norgaard, J.M., Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J. Clin. Oncol. 33:31 (2015), 3641–3649.
22. [22] Morton, L.M., Dores, G.M., Tucker, M.A., Kim, C.J., Onel, K., Gilbert, E.S., Fraumeni, J.F. Jr., Curtis, R.E., Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975–2008. Blood 121:15 (2013), 2996–3004.
23. [23] Flandrin, G., Classification of myelodysplasic syndromes. Atlas Genet. Cytogenet. Oncol. Haematol. 6:3 (2002), 220–225.
24. [24] Hirai, H., Molecular mechanisms of myelodysplastic syndrome. Jpn. J. Clin. Oncol. 33:4 (2003), 153–160.
25. [25] Cui, W., Sun, J., Cotta, C.V., Medeiros, L.J., Lin, P., Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia. Am. J. Clin. Pathol. 136:2 (2011), 282–288.
26. [26] Ma, S.K., Wan, T.S., Au, W.Y., Fung, L.F., So, C.K., Chan, L.C., Chromosome 11q deletion in myeloid malignancies. Leukemia 16:5 (2002), 953–955.
27. [27] Bilhou-Nabera, C., del(20q) in myeloid malignancies. Atlas Genet. Cytogenet. Oncol. Haematol. 5:1 (2001), 33–34.
28. [28] Musilova, J., Michalova, K., Jarosova, M., Chromosomes in myelodysplastic syndrome: structural abnormalities of chromosome 11. Czechoslovak MDS Cooperative Group. Ann. Genet. 32:1 (1989), 43–46.
29. [29] Thirman, M.J., Gill, H.J., Burnett, R.C., Mbangkollo, D., McCabe, N.R., Kobayashi, H., Ziemin-van der Poel, S., Kaneko, Y., Morgan, R., Sandberg, A.A., et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med. 329:13 (1993), 909–914.
30. [30] Johansson, B., Billstrom, R., Kristoffersson, U., Akerman, M., Garwicz, S., Ahlgren, T., Malm, C., Mitelman, F., Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 11:8 (1997), 1207–1213.
31. [31] Johansson, B., Billstrom, R., Mauritzson, N., Mitelman, F., Trisomy 19 as the sole chromosomal anomaly in hematologic neoplasms. Cancer Genet. Cytogenet. 74:1 (1994), 62–65.
32. [32] Olshanskaya, Y.V., Udovichenko, A.I., Vodinskaya, L.A., Glasko, E.N., Parovitchnikova, E.N., Lorie, Y.Y., Dvirnik, V.N., Savchenko, V.G., Domracheva, E.V., Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. Cancer Genet. Cytogenet. 167:1 (2006), 47–50.
33. [33] Pedersen-Bjergaard, J., Pedersen, M., Roulston, D., Philip, P., Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:9 (1995), 3542–3552.
34. [34] Pedersen-Bjergaard, J., Philip, P., Larsen, S.O., Jensen, G., Byrsting, K., Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:6 (1990), 1083–1091.
35. [35] Orazi, A., Czader, M.B., Myelodysplastic syndromes. Am. J. Clin. Pathol. 132:2 (2009), 290–305.
36. [36] Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lubbert, M., Kunzmann, R., Giagounidis, A.A., Aul, C., Trumper, L., Krieger, O., Stauder, R., Muller, T.H., Wimazal, F., Valent, P., Fonatsch, C., Steidl, C., New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:13 (2007), 4385–4395.
37. [37] Witherspoon, R.P., Deeg, H.J., Storer, B., Anasetti, C., Storb, R., Appelbaum, F.R., Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J. Clin. Oncol. 19:8 (2001), 2134–2141.
38. [38] Anderson, J.E., Gooley, T.A., Schoch, G., Anasetti, C., Bensinger, W.I., Clift, R.A., Hansen, J.A., Sanders, J.E., Storb, R., Appelbaum, F.R., Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89:7 (1997), 2578–2585.
39. [39] Armand, P., Kim, H.T., Mayer, E., Cutler, C.S., Ho, V.T., Koreth, J., Alyea, E.P., Antin, J.H., Soiffer, R.J., Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant 45:11 (2010), 1611–1617.
40. [40] Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., Silverman, L.R., International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10:3 (2009), 223–232.
41. [41] Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Te Boekhorst, P., Sanz, G., Del Canizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lubbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T., Hellstrom-Lindberg, E., M.D.S.L.d.q.S. Group, A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:14 (2011), 3765–3776.
42. [42] Armand, P., Kim, H.T., DeAngelo, D.J., Ho, V.T., Cutler, C.S., Stone, R.M., Ritz, J., Alyea, E.P., Antin, J.H., Soiffer, R.J., Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol. Blood Marrow Transplant 13:6 (2007), 655–664.
43. [43] Stemmer, S.M., Klang, S.H., Ben-Baruch, N., Geffen, D.B., Steiner, M., Soussan-Gutman, L., Merling, S., Svedman, C., Rizel, S., Lieberman, N., The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients. Breast Cancer Res. Treat. 140:1 (2013), 83–92.